Cooperative translational control of gene expression by Ras and Akt in cancer

Trends in Molecular Medicine

Volumn 10, Issue 12, 2004, Pages 607-613

  Parsa, Andrew T ^a   Holland, Eric C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; ELF2ALPHA PROTEIN; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN DERIVATIVE; PROTEIN KINASE B; RAS PROTEIN; S6 KINASE; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; CARCINOGENESIS; CODON; DISEASE COURSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FATALITY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOMA; HUMAN; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE RAS; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 9644278020     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.10.009     Document Type: Review

References (53)

1. W.C. Hahn, and R.A. Weinberg Rules for making human tumor cells N. Engl. J. Med. 347 2002 1593 1603
2. L.A. Loeb Multiple mutations and cancer Proc. Natl. Acad. Sci. U. S. A. 100 2003 776 781
3. W.C. Hahn, and R.A. Weinberg Modelling the molecular circuitry of cancer Nat. Rev. Cancer 2 2002 331 341
4. C.H. de Moor, and J.D. Richter Translational control in vertebrate development Int. Rev. Cytol. 203 2001 567 608
5. R. Sager Expression genetics in cancer: shifting the focus from DNA to RNA Proc. Natl. Acad. Sci. U. S. A. 94 1997 952 955
6. N. Sonenberg, and T.E. Dever Eukaryotic translation initiation factors and regulators Curr. Opin. Struct. Biol. 13 2003 56 63
7. A.C. Prats, and H. Prats Translational control of gene expression: role of IRESs and consequences for cell transformation and angiogenesis Prog. Nucleic Acid Res. Mol. Biol. 72 2002 367 413
8. G.S. Wilkie Regulation of mRNA translation by 5′- and 3′-UTR-binding factors Trends Biochem. Sci. 28 2003 182 188
9. H.A. Meijer, and A.A. Thomas Control of eukaryotic protein synthesis by upstream open reading frames in the 5′-untranslated region of an mRNA Biochem. J. 367 2002 1 11
10. S. Kuersten, and E.B. Goodwin The power of the 3′ UTR: translational control and development Nat. Rev. Genet. 4 2003 626 637
11. P. Mitchell, and D. Tollervey mRNA turnover Curr. Opin. Cell Biol. 13 2001 320 325
12. A.C. Gingras Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism Genes Dev. 13 1999 1422 1437
13. F. Meric, and K.K. Hunt Translation initiation in cancer: a novel target for therapy Mol. Cancer Ther. 1 2002 971 979
14. X. Wang The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation Mol. Cell. Biol. 23 2003 1546 1557
15. K. Khaleghpour Translational homeostasis: eukaryotic translation initiation factor 4E control of 4E-binding protein 1 and p70 S6 kinase activities Mol. Cell. Biol. 19 1999 4302 4310
16. S.R. Kimball Eukaryotic initiation factor eIF2 Int. J. Biochem. Cell Biol. 31 1999 25 29
17. M.J. Clemens Targets and mechanisms for the regulation of translation in malignant transformation Oncogene 23 2004 3180 3188
18. N. Pullen, and G. Thomas The modular phosphorylation and activation of p70s6k FEBS Lett. 410 1997 78 82
19. H.B. Jefferies Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k EMBO J. 16 1997 3693 3704
20. J. Avruch The p70 S6 kinase integrates nutrient and growth signals to control translational capacity Prog. Mol. Subcell. Biol. 26 2001 115 154
21. M. Li Differential effects of des IGF-1 on Erks, AKT-1 and P70 S6K activation in mouse skeletal and cardiac muscle Mol. Cell. Biochem. 236 2002 115 122
22. E.J. Uhlmann Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation Glia 47 2004 180 188
23. A.C. Gingras mTOR signaling to translation Curr. Top. Microbiol. Immunol. 279 2004 169 197
24. T. Schmelzle, and M.N. Hall TOR, a central controller of cell growth Cell 103 2000 253 262
25. A.C. Gingras Regulation of translation initiation by FRAP/mTOR Genes Dev. 15 2001 807 826
26. Garami, A. et al. (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. In. Mol. Cell 11, 1457-1466
27. L.J. Saucedo Rheb promotes cell growth as a component of the insulin/TOR signalling network Nat. Cell Biol. 5 2003 566 571
28. Y. Zhang Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins Nat. Cell Biol. 5 2003 578 581
29. M.N. Corradetti Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome Genes Dev. 18 2004 1533 1538
30. R.J. Shaw The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress Proc. Natl. Acad. Sci. U. S. A. 101 2004 3329 3335
31. R.J. Shaw The LKB1 tumor suppressor negatively regulates mTOR signaling Cancer Cell 6 2004 91 99
32. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat. Rev. Cancer 2 2002 489 501
33. M.L. Sulis, and R. Parsons PTEN: from pathology to biology Trends Cell Biol. 13 2003 478 483
34. V. Stambolic Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN Cell 95 1998 29 39
35. L.C. Cantley, and B.G. Neel New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway Proc. Natl. Acad. Sci. U. S. A. 96 1999 4240 4245
36. M.F. Olson, and R. Marais Ras protein signalling Semin. Immunol. 12 2000 63 73
37. J.L. Bos The ras gene family and human carcinogenesis Mutat. Res. 195 1988 255 271
38. M.M. Feldkamp Signal transduction pathways and their relevance in human astrocytomas J. Neurooncol. 35 1997 223 248
39. D.A. Antonetti Regulation of rDNA transcription by insulin in primary cultures of rat hepatocytes J. Biol. Chem. 268 1993 25277 25284
40. G.C. Scheper The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells Mol. Cell. Biol. 21 2001 743 754
41. V.K. Rajasekhar Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes Mol. Cell 12 2003 889 901
42. E.C. Holland Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice Nat. Genet. 25 2000 55 57
43. Y. Sonoda Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma Cancer Res. 61 2001 6674 6678
44. H. Dong B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat. Med. 5 1999 1365 1369
45. H. Dong Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat. Med. 8 2002 793 800
46. H. Dong, and L. Chen B7-H1 pathway and its role in the evasion of tumor immunity J. Mol. Med. 81 2003 281 287
47. M. Hidalgo, and E.K. Rowinsky The rapamycin-sensitive signal transduction pathway as a target for cancer therapy Oncogene 19 2000 6680 6686
48. S. Huang, and P.J. Houghton Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic Curr. Opin. Investig. Drugs 3 2002 295 304
49. J.E. Dancey Clinical development of mammalian target of rapamycin inhibitors Hematol. Oncol. Clin. North Am. 16 2002 1101 1114
50. S. Huang Rapamycins: mechanism of action and cellular resistance Cancer Biol. Ther. 2 2003 222 232
51. S. Huang, and P.J. Houghton Targeting mTOR signaling for cancer therapy Curr. Opin. Pharmacol. 3 2003 371 377
52. P.J. Houghton, and S. Huang mTOR as a target for cancer therapy Curr. Top. Microbiol. Immunol. 279 2004 339 359
53. M.S. Neshat Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc. Natl. Acad. Sci. U. S. A. 98 2001 10314 10319